Search
Esflurbiprofen
go.drugbank.com/drugs/DB16159InvestigationalEsflurbiprofen is under investigation in clinical trial NCT03434197 (Safety and Efficacy of SFPP in Knee Osteoarthritis).
Categories: Topical Products for Joint and Muscular Pain, Antiinflammatory Preparations, Non-Steroids for Topical UseFenfluramine
go.drugbank.com/drugs/DB00574ApprovedIllicitInvestigationalWithdrawn[A214688, A214691, A214700] Fenfluramine was granted initial FDA approval in 1973 prior to its withdrawal; it was granted a new FDA approval on June 25, 2020, for treatment of patients with Dravet syndrome
Categories: Serotonin Receptor Agonists, Serotonin 5-HT2 Receptor AgonistsBirinapant
go.drugbank.com/drugs/DB11782InvestigationalBirinapant has been investigated for the treatment of Myelodysplastic Syndrome (MDS) and Chronic Myelomonocytic Leukemia (CMML).
Icariin
go.drugbank.com/drugs/DB12052InvestigationalIcariin has been investigated for the basic science of the Pharmacokinetic Profile of Icariin in Humans.
123I-iodometomidate
go.drugbank.com/drugs/DB13021Investigational123I-iodometomidate is under investigation in clinical trial NCT00454103 (Evaluation of 123I-Iodometomidate for Adrenal Scintigraphy).
Rivenprost
go.drugbank.com/drugs/DB16315InvestigationalRivenprost is under investigation in clinical trial NCT00296556 (Therapeutic Study of ONO-4819CD for Ulcerative Colitis).
JTC-801 free base
go.drugbank.com/drugs/DB17033ExperimentalAn antagonist of nociceptin receptor and analgesic agent, evaluated for its use in cancer treatment.[A253027]
Suvodirsen
go.drugbank.com/drugs/DB17940InvestigationalSuvodirsen is an antisense oligonucleotide that has been investigated for the treatment of Duchenne muscular dystrophy.
ART5803
go.drugbank.com/drugs/DB18379InvestigationalART5803 is a humanized one-armed monoclonal antibody with a high affinity for the NMDA receptor.
Rugonersen
go.drugbank.com/drugs/DB18662InvestigationalRugonersen is a locked nucleic acid antisense oligonucleotide under investigation for the treatment of Angelman Syndrome.